Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Genetic testing for inherited ovarian cancer (without breast cancer) (R207)

Testing strategy

Clinically affected probands:

R207.1 - analysis for small variants in the gene panel indicated below.

R207.2 - dosage analysis for copy number variants in the gene panel below (NHSE test indication requires analysis only of BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 but methodology used assesses dosage of all genes included in the panel).

NHSE funded test referrals should meet the relevant NHSE eligibility criteria (pdf).

Genes tested:

Genes analysed are in accordance with the 'green' high evidence of clinical association gene list in panel app.

Targeted analysis for known / previously reported familial variants:

  • Presymptomatic testing in clinically unaffected family members at risk of inheriting a previously reported familial pathogenic variant (R242)
  • Diagnostic confirmation in individuals at risk of inheriting a previously reported familial pathogenic variant and clinically suspected of having the familial condition (R240)
  • Segregation studies in affected family members to aid variant interpretation (R375)
  • Prenatal diagnosis is not typically requested

Sample requirements and referral information

Requesting specialty: Clinical Genetics

Specimen requirements and referring samples

Price list for non NHSE referrals (pdf)

Contact us


Last reviewed:02 August 2021